And while we expect there may be some quarterly volatility, we think the initiatives that the company has recently put in place to revive sales of Calmare, including re-establishment of their international footprint, wider U.S. distribution, increased penetration of the U.S. government channel and building awareness of the potential benefits of Calmare therapy should result in continued, yet perhaps measured, sales growth. As noted, on the Q3 call management mentioned that they expect to make a GSA-related announcement in the coming weeks - while no specifics were provided, we interpret the message to be that this could help catalyze an increase in sales to the government channel.
